Coegin PharmaNGM:COEGIN +5.43%29 Market Cap is kr93.95 Mil as of Jul. 01, 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,427 Biotechnology companies, Coegin Pharma ranks worse than 84.86% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Coegin Pharma's share price for the quarter that ended in Mar. 2026 was kr3.89. Coegin Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 28.59 Mil. Therefore, Coegin Pharma's market cap for the quarter that ended in Mar. 2026 was kr111.22 Mil.
Coegin Pharma's quarterly market cap
declined
from Sep. 2025 (kr196.54 Mil) to Dec. 2025 (kr110.46 Mil) but then
increased
from Dec. 2025 (kr110.46 Mil) to Mar. 2026 (kr111.22 Mil).
Coegin Pharma's annual market cap
increased
from Dec. 2023 (kr45.02 Mil) to Dec. 2024 (kr95.78 Mil) and
increased
from Dec. 2024 (kr95.78 Mil) to Dec. 2025 (kr110.46 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Coegin Pharma's Enterprise Value for Today is kr84.68 Mil.
Coegin Pharma (NGM:COEGIN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Coegin Pharma Market Cap Related Terms
Coegin Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Coegin Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Coegin Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coegin Pharma (NGM:COEGIN) has a Market Cap of kr93.95 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Coegin Pharma and its competitors. According to the industry distribution chart, Coegin Pharma ranks #1211 out of 1427 companies in the Biotechnology industry, placing it in the top 84.9%.
Is Coegin Pharma's Market Cap too high?
Coegin Pharma's current Market Cap is kr93.95 Mil. Based on the distribution chart, Coegin Pharma ranks #1211 out of 1427 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #1211 out of 1427 companies for Market Cap. This places Coegin Pharma in the lower half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Coegin Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coegin Pharma's current Market Cap is kr93.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Market Cap of kr93.95 Mil. The current Market Cap is kr93.95 Mil. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Market Cap is kr93.95 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score
Get the complete analysis for NGM:COEGIN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
